IV 
119TH CONGRESS 
1ST SESSION 
H. RES. 394 
Expressing support for the designation of July 16, 2025, as ‘‘Glioblastoma 
Awareness Day’’. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 6, 2025 
Mr. WILLIAMS of Texas (for himself, Mr. MAST, Ms. SCHAKOWSKY, and Mr. 
AUCHINCLOSS) submitted the following resolution; which was referred to 
the Committee on Energy and Commerce 
RESOLUTION 
Expressing support for the designation of July 16, 2025, 
as ‘‘Glioblastoma Awareness Day’’. 
Whereas it is estimated that more than 13,000 Americans 
will be diagnosed with glioblastoma in 2025; 
Whereas glioblastoma is— 
(1) the most common malignant (cancerous) brain 
tumor, accounting for approximately 1⁄2 of all primary 
malignant brain tumors; and 
(2) the most aggressive, complex, difficult to treat, 
and deadly type of brain tumor; 
Whereas it is estimated that more than 10,000 individuals in 
the United States will succumb to glioblastoma each year; 
VerDate Sep 11 2014 
22:19 May 06, 2025
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR394.IH
HR394
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 394 IH 
Whereas the 5-year survival rate for glioblastoma patients is 
only 6.9 percent, and the median length of survival for 
glioblastoma patients is only 8 months; 
Whereas glioblastoma is described as a disease that affects 
the ‘‘essence of self’’, as the treatment and removal of 
glioblastoma presents significant challenges due to the 
uniquely complex and fragile nature of the brain, the pri-
mary organ in the human body that controls not only 
cognitive ability, but also the actions of every organ and 
limb; 
Whereas patients and caregivers play a critical role in fur-
thering research for glioblastoma; 
Whereas, relative to other types of cancers, brain cancer pa-
tients pay the second highest out-of-pocket costs for med-
ical services in both the initial and end-of-life phases of 
care; 
Whereas, although research advances may fuel the develop-
ment of new treatments for glioblastoma, challenging ob-
stacles to accelerating progress toward new treatments 
for glioblastoma remain, and there are no screening or 
early detection methods; 
Whereas, in 2021, significant changes were made to the mo-
lecular characteristics of a glioblastoma diagnosis, neces-
sitating critical biomarker testing for patients suspected 
of having a possible glioblastoma; 
Whereas, although glioblastoma was first described in medical 
and scientific literature in the 1920s, and despite its dev-
astating prognosis, only 5 drugs and 1 medical device 
have been approved by the Food and Drug Administra-
tion to specifically treat glioblastoma since the 1920s, 
VerDate Sep 11 2014 
22:19 May 06, 2025
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR394.IH
HR394
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 394 IH 
and the mortality rates associated with glioblastoma have 
changed little during the past 30 years; 
Whereas, since the first Glioblastoma Awareness Day, the 
National Cancer Institute established the Glioblastoma 
Therapeutics Network (referred to in this preamble as 
‘‘GTN’’) in 2020 as part of a national infrastructure to 
enhance and support the discovery and development of 
glioblastoma therapies available for multi-institutional 
GTN teams to drive therapeutic agents through pre-
clinical studies and early phase clinical trials, which are 
necessary to rapidly evaluate potential treatments to ad-
vance toward cures and improved quality of life; 
Whereas there is a need for greater public awareness of glio-
blastoma, including awareness of both— 
(1) the urgent unmet medical needs of glioblastoma 
patients; and 
(2) the opportunities for research of, and treatment 
advances for, glioblastoma; and 
Whereas the House of Representatives supports designating 
July 16, 2025, as ‘‘Glioblastoma Awareness Day’’: Now, 
therefore, be it 
Resolved, That the House of Representatives— 
(1) expresses support for the designation of 
‘‘Glioblastoma Awareness Day’’; 
(2) encourages increased public awareness of 
glioblastoma; 
(3) honors the individuals who have died from 
the devastating disease of glioblastoma or are cur-
rently living with the disease; 
VerDate Sep 11 2014 
22:19 May 06, 2025
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\HR394.IH
HR394
ssavage on LAPJG3WLY3PROD with BILLS
•HRES 394 IH 
(4) supports efforts to develop better treat-
ments for glioblastoma that will improve the long- 
term prognosis for, and the quality of life of, individ-
uals diagnosed with the disease; 
(5) recognizes the importance of molecular bio-
marker testing to the diagnosis and treatment of 
glioblastoma; 
(6) expresses support for the individuals who 
are battling brain tumors, as well as the families, 
friends, and caregivers of those individuals; 
(7) urges a collaborative approach to brain 
tumor research among governmental, private, and 
nonprofit organizations, which is a promising means 
of advancing the understanding and treatment of 
glioblastoma; and 
(8) encourages continued investments in glio-
blastoma research and treatments, including through 
the Glioblastoma Therapeutics Network and other 
existing brain tumor research resources. 
Æ 
VerDate Sep 11 2014 
22:19 May 06, 2025
Jkt 059200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR394.IH
HR394
ssavage on LAPJG3WLY3PROD with BILLS